This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A review of EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Ticker(s): EDIT, VRTX, BLUE, CRSPWho's the expert?
Institution: Boston Medical Center
- Associate professor of Pediatrics at Boston University Chobanian & Avedisian School of Medicine
- Hematologist/Oncologist who sees 200 patients with Sickle Cell Disease
- Research interests focus on quality of care in sickle cell disease, and transition from pediatric to adult care.
Interview GoalDiscussing the potential of Editas Medicines' EDIT-301 and the recent results from the RUBY trial, a single-arm, open-label, multi-center Phase 1/2 study
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
